Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-22
2011-03-22
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
07910566
ABSTRACT:
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
REFERENCES:
patent: 4497817 (1985-02-01), Murase et al.
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6372249 (2002-04-01), Smith et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6593353 (2003-07-01), Gudkov et al.
patent: 6982277 (2006-01-01), Gudkov et al.
patent: 7008956 (2006-03-01), Gudkov et al.
patent: 7012087 (2006-03-01), Gudkov et al.
patent: 7781575 (2010-08-01), Khvorova et al.
patent: 2002/0019425 (2002-02-01), Gudkov et al.
patent: 2004/0014956 (2004-01-01), Woolf et al.
patent: 2004/0180351 (2004-09-01), Giese et al.
patent: 2004/0209832 (2004-10-01), McSwiggen et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2005/0222224 (2005-10-01), Gudkov et al.
patent: 2006/0069056 (2006-03-01), Feinstein et al.
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0185047 (2007-08-01), Bhat et al.
patent: 2008/0108583 (2008-05-01), Feinstein et al.
patent: 2008/0287382 (2008-11-01), Feinstein et al.
patent: 2009/0082291 (2009-03-01), Feinstein et al.
patent: 2010/0029746 (2010-02-01), Feinstein et al.
patent: 0 430 334 (1991-06-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/55693 (2002-07-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2004/031237 (2004-04-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2006/035434 (2006-04-01), None
Amarzguioui et al. (2003), “Tolerance for mutations and chemical modifications in a siRNA,” Nucleic Acids Research, 31(2): 589-595, 2003.
Barik, Sailen (2005). “Silence of the Transcripts; RNA Interference In Medicine,” J. Mol. Med. 83:764-773.
Bartel, David P. et al. (2004). “MicroRNAs: Genomics Biogenesis, Mechanism, and Function,” Cell, 116:281-297.
Bernstein, Emily et al. (2001). “Role For a Bidentate Ribonuclease in the Initiation Step of RNA Interference,” Nature, 409:363-366.
Bertrand et al. (2002). “Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo,” Biochemical and Biophysical Research Communications, 296:1000-1004.
Bitko, Vira et al. (2004). “Inhibition of Respiratory Viruses By Nasally Administered siRNA,” Nature Medicine, 11(1):50-55.
Botchkarev, V.A., et al., (2000). “p53 Is Essential for Chemotherapy-induced Hair Loss,” Cancer Res. 60:5002-5006.
Brummelkamp, Thijn R. et al. (2002). “A System For Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, 296: 550-553.
Caplen, Natasha J. et al. (2001). “Specific Inhibition of Gene Expression By Small Double-Stranded RNAs in Invertebrate Vertebrate Systems,” PNAS, 98(17):9742-9747.
Chakraborty, Chiranjib (2007). “Potentiality of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing,” Current Drug Targets, 8:469-482.
Chalk, Alistair M. et al., (2004). “Improved and Automated Prediction of Effective siRNA,” Biochemical and Biophysical Research Communications, 319:264-274.
Chernov, M.V. and Stark, G.R., (1997). “The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate,” Oncogene 14:2503-2510.
Cotsarelis, G. and Millar, S.E., (2001). “Towards a molecular understanding of hair loss and its treatment,” Trends Mol. Med. 7(7):293-301.
Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. (2003). “Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells,” Nucleic Acids Res. 31(11):2705-16.
Elbashir, Sayda M. et al. (2001). “RNA Interference is Mediated by 21- and 22-nucleotide RNAs,” Genes & Development, 15:188-200.
Elbashir, Sayda M. et al. (2001). “Duplexes of 21-nucleotide RNAs mediated RNA interference in cultured mammalian cells,” Nature, 411:494-498.
Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. (2001). “Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembroyo lysate,” EMBO J. 20(23):6877-88.
Fire, Andrew et al., (1998). “Potent and Specific Genetic Interference by Double-stranded RNA inCaenorhabditis elegans,” Nature, 391:806-811.
Gottlieb, T.M., et al., (1996). “p53 in growth control and neoplasia,” Biochim Biophys Acta 1287:77-102.
Holen et al., (2002). Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor, Nucleic Acids Research, 30(8):1757-1766.
Komarov, P.G., et al., (1999). “A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy,” Science 285:1733-1737.
Komarova, E.A., et al., (1997). 'Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo, EMBO J. 16(6):1391-1400.
Lee, Youngtae et al., (2003). “The nuclear RNase III Drosha initiates microRNA processing,” Nature, 425:415-419.
Levenkova, Natasha et al., (2004). “Gene specific siRNA selector,” Bioinformatics, 20(3):430-432.
Mahato et al. (2005). “Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA”, Expert Opinion on Drug Delivery, 2(1):3-28.
McManus, Michael T. and Sharp, Phillip A., (2002). “Gene Silencing in Mammals by Small Interfering RNAs,” Genetics, 3:737-747.
Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, Baker BF, Swayze EE, Griffey RH, Bhat B. (2005). “Positional effect of chemical modifications on short interference RNA activity in mammalian cells,” J Med Chem. 48(13):4247-53.
Scherer et al. (2003). “Approaches for the sequence-specific knockdown of mRNA,” Nat. Biotechnol., 21 (12):1457-1465.
Schomber et al. (2004). “Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells,” Blood, 103(12):4511-4513.
Sioud, Moudly and Leirdal, Marianne, (2004). “Potential Design Rules and Enzymatic Synthesis of siRNAs,” Methods in Molecular Biology, 252:457-468.
Steele, R.J.C., et al., (1998). “The p53 tumour suppressor gene,” Br. J. Surg. 85:1460-1467.
Supavekin, S., et al., (2003). “Differential gene expression following early renal ischemia/reperfusion,” Kidney Int. 63:1714-1724.
Tekippe, M., et al., (2003). “Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice,” Exp. Hematol. 31:521-527.
Tolentino, Michael J. et al., (2004). “Intravitreal Injection of Vascular Endothelial Growth Factor Small Interfering RNA Inhibits Growth and Leakage in a Nonhuman Primate, Laser-induced Model of Choroidal Neovascularization,” Retina, The Journal of Retinal and Vitreous Diseases, 24(1):132-138.
Ui-Tei, Kumiko et al., (2004). “Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference,” Nucleic Acids Research, 32(3):936-948.
Wang, J. et al., (2003). “A Peptide Inhibitor of c-Jun N-Terminal Kinase Protects against Both Aminoglycoside and Acoustic Trauma-Induced Auditory
Bowman Amy
Cooper & Dunham LLP
Quark Pharmaceuticals Inc.
White John P.
LandOfFree
Prevention and treatment of acute renal failure and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of acute renal failure and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of acute renal failure and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742833